Abstract:Immune thrombocytopenia（ITP）is an autoimmune hemorrhagic disease that occurs in 1 in 1 000 to 10 000 pregnancies.However，the treatment of ITP during pregnancy remains challenging. In particular，clinical treatment options are very limited for pregnant ITP patients who do not respond well to corticosteroids and intravenous immunoglobulin（IVIG）. There is a critical need for novel therapeutic approaches for ITP specifically designed for use in pregnant patients. The advent of thrombopoietic agents have led to a major change in the management of ITP. However，recombinant human thrombopoietin（rhTPO）is predominantly used only in China，while thrombopoietin receptor agonists（TPO-RA）lack high-level clinical evidence and may affect the fetus through placental transfer.There remains no international consensus regarding the use of thrombopoietic agents for treating ITP during pregnancy. This article mainly reviews the mechanism of action of thrombopoietic agents，the efficacy and safety in pregnant ITP，and provides a reference for the clinical application of thrombopoietic agents in pregnant ITP.